nach oben

Strahlentherapie und Onkologie

Erschienen in:

01.03.2014 | Original article

Association of genetic variants in apoptosis genes FAS and FASL with radiation-induced late toxicity after prostate cancer radiotherapy

verfasst von: E.-M. Thurner, S. Krenn-Pilko, U. Langsenlehner, W. Renner, A. Gerger, K.S. Kapp, T. Langsenlehner, MD

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

Fas ligand (FASL) triggers apoptotic cell death by cross-linking with its receptor FAS, and after irradiation, expression of FAS and FASL is increased. In the present study, we investigated the association between common polymorphisms in the genes for FAS and FASL and the risk of late side effects after radiotherapy for prostate cancer.

Patients and methods

The role of FAS (− 1377G > A, rs2234767 and − 670A > G, rs1800682) and FASL (− 844C > T, rs763110) gene polymorphisms in the development of high-grade late rectal and/or urinary toxicity (defined as late toxicity EORTC/RTOG grade ≥ 2) was analyzed in 607 prostate cancer patients treated with radiotherapy. DNA was isolated and the selected polymorphisms were determined by 5’-nuclease (TaqMan) assays.

Results

After a median follow-up time of 82 months, high-grade late rectal and/or urinary toxicity was observed in 175 patients (29.7 %). Univariate analysis revealed a significantly decreased risk of high-grade late toxicity in carriers of the FASL − 844T allele. After adjusting for covariates, patients harboring at least one − 844T allele (CT or TT genotype) remained at decreased risk of high-grade late toxicity compared with patients harboring the CC genotype [hazard ratio (HR) 0.585, 95 %CI 0.39–0.878; p = 0.010]. For patients with the − 844TT genotype, the HR was 0.404 (95 %CI 0.171–0.956; p = 0.039) in multivariate analysis. No significant associations were found for the remaining polymorphisms analyzed.

Conclusions

These results provide the first evidence that the presence of the FASL − 844T variant allele may have a protective effect against the development of high-grade late rectal and/or urinary side effects after prostate cancer radiotherapy.

Belka C, Marini P, Budach W et al (1998) Radiation induced apoptosis in human lymphocytes and lymphoma cells critically relies on the up- regulation of CD95/Fas/APO-1 ligand. Radiat Res 149:588–595PubMedCrossRef

Blattmann C, Thiemann M, Stenzinger A et al (2012) Radiosensitization by histone deacetylase inhibition in an osteosarcoma mouse model. Strahlenther Onkol 188:1038–1047CrossRef

Bunz F, Hwang PM, Torrance C et al (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104:263–269PubMedCentralPubMedCrossRef

Chang-Claude J, Ambrosone CB, Lilla C et al (2009) Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer. Br J Cancer 100:1680–1686PubMedCentralPubMedCrossRef

Chen L, Park SM, Tumanov AV et al (2010) CD95 promotes tumour growth. Nature 465:492–496PubMedCentralPubMedCrossRef

Cordes N, Rödel F, Rodemann HP (2012) Molecular signaling pathways. Mechanisms and clinical use. Strahlenther Onkol 188:308–311PubMedCrossRef

Fulda S, Debatin KM (2006) Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25:4798–4811PubMedCrossRef

Greve B, Sheikh-Mounessi F, Kemper B et al (2012) Survivin, a target to modulate the radiosensitivity of Ewing’s sarcoma. Strahlenther Onkol 188:1038–1047PubMedCrossRef

Gudkov AV, Komarova EA (2003) The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 3:117–129PubMedCrossRef

10.

Heinzelmann F, Jendrossek V, Lauber K et al (2006) Irradiation-induced pneumonitis mediated by the CD95/CD95-ligand system. J Natl Cancer Inst 98:1248–1251PubMedCrossRef

11.

Houston A, O’Connell J (2004) The Fas signalling pathway and its role in the pathogenesis of cancer. Curr Opin Pharmacol 4:321–326PubMedCrossRef

12.

Huang QR, Morris D, Manolios N (1997) Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 34:577–582PubMedCrossRef

13.

Jung H, Beck-Bornholdt HP, Svoboda V et al (2012) Late complications after radiotherapy for prostate cancer. Strahlenther Onkol 188:965–974PubMedCrossRef

14.

Kanemitsu S, Ihara K, Saifddin A et al (2002) A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol 29:1183–1188PubMed

15.

Long JS, Ryan KM (2012) New frontiers in promoting tumour cell death: targeting apoptosis, necroptosis and autophagy. Oncogene 31:5045–5060PubMedCrossRef

16.

Lord CJ, Ashworth A (2012) The DNA damage response and cancer therapy. Nature 481:287–294PubMedCrossRef

17.

Lowe SW, Cepero E, Evan G (2004) Intrinsic tumour suppression. Nature 432:307–315PubMedCrossRef

18.

Luce A, Courtin A, Levalois C et al (2009) Death receptor pathways mediate targeted and non-targeted effects of ionizing radiations in breast cancer cells. Carcinogenesis 30:432–439PubMedCentralPubMedCrossRef

19.

Neff TA, Guo RF, Neff SB et al (2011) Relationship of acute lung inflammatory injury to Fas/FasL system. Transplantation 92:523–528PubMedCrossRef

20.

Nishioka A, Ogawa Y, Kubonishi I et al (1999) An augmentation of Fas (CD95/APO 1) antigen induced by radiation: flow cytometry analysis of lymphoma and leukemia cell lines. Int J Mol Med 3:275–278PubMed

21.

O’Connell J, Bennett MW, O’Sullivan GC et al (1999) The Fas counterattack: cancer as a site of immune privilege. Immunol Today 20:46–52CrossRef

22.

Rzeszowska-Wolny J, Przybyszewski WM, Widel M (2009) Ionizing radiation-induced bystander effects, potential targets for modulation of radiotherapy. Eur J Pharmacol 625:156–164PubMedCrossRef

23.

Sibley K, Rollinson S, Allan JM et al (2003) Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 63:4327–4330PubMed

24.

Simstein R, Burow M, Parker A et al (2003) Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Exp Biol Med (Maywood) 228:995–1003

25.

Sun T, Miao X, Zhang X et al (2004) Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 96:1030–1036PubMedCrossRef

26.

Tan XL, Popanda O, Ambrosone CB et al (2006) Association between TP53 and p21 genetic polymorphisms and acute side effects of radiotherapy in breast cancer patients. Breast Cancer Res Treat 97:255–262PubMedCrossRef

27.

Tsoutsou PG, Koukourakis MI (2006) Radiation pneumonitis and fibrosis: mechanisms underlying its pathogenesis and implications for future research. Int J Radiat Oncol Biol Phys 66:1281–1293PubMedCrossRef

28.

Wang W, Zheng Z, Yu W et al (2012) Polymorphisms of the FAS and FASL genes and risk of breast cancer. Oncol Lett 3:625–628PubMedCentralPubMed

29.

Wu J, Metz C, Xu X et al (2003) A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol 170:132–138PubMedCrossRef

30.

Wu J, Richards MH, Huang J et al (2011) Human FasL gene is a target of β-catenin/T-cell factor pathway and complex FasL haplotypes alter promoter functions. PLoS One 6:e26143PubMedCentralPubMedCrossRef

31.

Yang M, Sun T, Wang L et al (2008) Functional variants in cell death pathway genes and risk of pancreatic cancer. Clin Cancer Res 14:3230–3236PubMedCrossRef

32.

Yang M, Zhang L, Bi N et al (2011) Association of P53 and ATM polymorphisms with risk of radiation-induced pneumonitis in lung cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 79:1402–1407PubMedCrossRef

33.

Zhang B, Sun T, Xue L et al (2007) Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 28:1067–1073PubMedCrossRef

34.

Zhou L, Yuan R, Serggio L (2003) Molecular mechanisms of irradiation-induced apoptosis. Front Biosci 8:d9–d19PubMedCentralPubMedCrossRef

Titel: Association of genetic variants in apoptosis genes FAS and FASL with radiation-induced late toxicity after prostate cancer radiotherapy
verfasst von: E.-M. Thurner
S. Krenn-Pilko
U. Langsenlehner
W. Renner
A. Gerger
K.S. Kapp
T. Langsenlehner, MD
Publikationsdatum: 01.03.2014
Verlag: Springer-Verlag
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 3/2014
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-013-0485-0

Springer Medizin

Association of genetic variants in apoptosis genes FAS and FASL with radiation-induced late toxicity after prostate cancer radiotherapy